R

Research by Design, LLC | Chicago, IL

Research site

(Unclaimed)

Location

10801 South Western Avenue, Suite 201, Chicago, Illinois, United States of America

Site insights

Top conditions

Top treatments

BI 685509

MB-102

Calcifediol

PF-07321332

Ritonavir

Relmapirazin

Finerenone

Paricalcitol

MK-8527-008

sodium chloride

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 24 total trials

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability...

Active, not recruiting

Renal Impairment

Drug: MK-8527

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Primary Objectives* To assess the safety and tolerability of RGLS8429* To assess the impact of RGLS8429 on ADPKD biomarkersSecondary Objectives* To a...

Enrolling

ADPKD

Polycystic Kidney, Autosomal Dominant

Drug: Placebo

Drug: RGLS8429

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling

Obesity

Drug: Placebo

Drug: survodutide

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting

Non-diabetic Chronic Kidney Disease

Drug: Finerenone (BAY94-8862)

Drug: Placebo

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)